期刊
LEUKEMIA RESEARCH
卷 28, 期 5, 页码 495-507出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2003.09.011
关键词
chronic lymphocytic leukemia; alemtuzumab; apoptosis; complement; cytotoxicity
资金
- NCI NIH HHS [1-R24 CA82899] Funding Source: Medline
- NCRR NIH HHS [1 P20 RR 16460] Funding Source: Medline
- NIDDK NIH HHS [DK58324-01] Funding Source: Medline
The mechanism of action of alemtuzumab (CAMPATH 1H) in chronic lymphocytic leukemia (CLL) is uncertain. We tested the hypothesis that alemtuzumab alone can induce apoptosis in cultured CLL cells. Purified peripheral blood B-lymphocytes from CLL patients were treated in serum free medium (AIM-V). There was minimal spontaneous apoptosis in untreated cells. Alemtuzumab ligation did not alter the membrane distribution of CD52 in single cells but many cells formed transient, small, tightly adherent clusters. Alemtuzumab alone did not induce apoptosis. In contrast, alemtuzumab plus complement was rapidly cytotoxic. We conclude that alemtuzumab does not cause apoptosis in purified CLL B cells cultured in serum free medium. (C) 2003 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据